CN112805302A - 抗BCMA单链抗体scFv及其制备方法和应用 - Google Patents

抗BCMA单链抗体scFv及其制备方法和应用 Download PDF

Info

Publication number
CN112805302A
CN112805302A CN201880098546.1A CN201880098546A CN112805302A CN 112805302 A CN112805302 A CN 112805302A CN 201880098546 A CN201880098546 A CN 201880098546A CN 112805302 A CN112805302 A CN 112805302A
Authority
CN
China
Prior art keywords
seq
sequence
chain variable
variable region
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880098546.1A
Other languages
English (en)
Other versions
CN112805302B (zh
Inventor
王媚娘
欧阳冰洁
杨乃波
姜琳
任丙昭
柳阳
赵正琦
李波
侯勇
王飞
葛玉萍
董旋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGI Shenzhen Co Ltd
Original Assignee
BGI Shenzhen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BGI Shenzhen Co Ltd filed Critical BGI Shenzhen Co Ltd
Publication of CN112805302A publication Critical patent/CN112805302A/zh
Application granted granted Critical
Publication of CN112805302B publication Critical patent/CN112805302B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供一种抗BCMA单链抗体scFv及其制备方法，包括结合定点突变和随机突变技术人工合成了靶向BCMA的噬菌体展示库，结合噬菌体展示技术，获得3株靶向BCMA抗原的新型scFv株，可作为靶向BCMA的抗体。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201880098546.1A 2018-10-10 2018-10-10 抗BCMA单链抗体scFv及其制备方法和应用 Active CN112805302B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/109564 WO2020073215A1 (zh) 2018-10-10 2018-10-10 抗BCMA单链抗体scFv及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN112805302A true CN112805302A (zh) 2021-05-14
CN112805302B CN112805302B (zh) 2023-01-31

Family

ID=70164445

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880098546.1A Active CN112805302B (zh) 2018-10-10 2018-10-10 抗BCMA单链抗体scFv及其制备方法和应用

Country Status (5)

Country Link
US (1) US20210246220A1 (zh)
EP (1) EP3854815A4 (zh)
JP (1) JP7126624B2 (zh)
CN (1) CN112805302B (zh)
WO (1) WO2020073215A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114763383A (zh) * 2021-01-13 2022-07-19 博生吉医药科技(苏州)有限公司 靶向人bcma的单克隆抗体及其应用
CN114276447B (zh) * 2021-12-31 2023-04-18 上海交通大学 一种牛源抑制金黄色葡萄球菌生长的单链抗体及其制备方法和用途
CN114292333B (zh) * 2021-12-31 2023-04-18 上海交通大学 一种牛源抗金黄色葡萄球菌凝固酶Coa的单链抗体、制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102978713A (zh) * 2012-11-23 2013-03-20 浙江大学 一种白血病单链抗体库及其构建方法和应用
US20170240644A1 (en) * 2015-06-09 2017-08-24 Beijing Dongfang Biotech Co., Ltd. Anti-pd-1 monoclonal antibody and obtaining method therefor
CN107208047A (zh) * 2014-12-05 2017-09-26 纪念斯隆-凯特琳癌症中心 靶向b‑细胞成熟抗原的嵌合抗原受体及其用途
CN108018299A (zh) * 2016-11-01 2018-05-11 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046722A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 イオン濃度依存性結合分子ライブラリ
MY181834A (en) * 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
KR101694832B1 (ko) * 2014-12-31 2017-01-12 앱클론(주) 항체 라이브러리 및 그의 제작방법
US10925969B2 (en) * 2015-11-13 2021-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Service Anti-BCMA polypeptides and proteins
CN105837693A (zh) * 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102978713A (zh) * 2012-11-23 2013-03-20 浙江大学 一种白血病单链抗体库及其构建方法和应用
CN107208047A (zh) * 2014-12-05 2017-09-26 纪念斯隆-凯特琳癌症中心 靶向b‑细胞成熟抗原的嵌合抗原受体及其用途
US20170240644A1 (en) * 2015-06-09 2017-08-24 Beijing Dongfang Biotech Co., Ltd. Anti-pd-1 monoclonal antibody and obtaining method therefor
CN108018299A (zh) * 2016-11-01 2018-05-11 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FELIX ODEN ET AL: "Potent anti-tumor response by targeting B cell maturation antigen(BCMA) in a mouse model of multiple myeloma", 《MOLECULAR ONCOLOGY》 *
张航等: "B细胞成熟抗原的抗肿瘤免疫治疗研究进展", 《药物生物技术》 *

Also Published As

Publication number Publication date
JP2022508775A (ja) 2022-01-19
US20210246220A1 (en) 2021-08-12
EP3854815A1 (en) 2021-07-28
CN112805302B (zh) 2023-01-31
WO2020073215A1 (zh) 2020-04-16
EP3854815A9 (en) 2021-12-08
EP3854815A4 (en) 2022-03-16
JP7126624B2 (ja) 2022-08-26

Similar Documents

Publication Publication Date Title
CN108250296B (zh) 全人源抗人pd-l1单克隆抗体及其应用
CN108285485B (zh) 一种抗pd-1的单域抗体及其应用
CN110642951B (zh) 一种抗ca125糖类抗原的高中和活性纳米抗体及其应用
CN112805302B (zh) 抗BCMA单链抗体scFv及其制备方法和应用
EP4043491B1 (en) B7-h3 nanobody and preparation method therefor and use thereof
CN114621345B (zh) 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN114262377B (zh) 一种阻断cd70与其配体cd27结合的抗人cd70纳米抗体的制备方法及其编码序列
CN112028997B (zh) 抗ceacam5纳米抗体
CN110713539B (zh) 一种抗癌胚抗原的抗体及其制备方法和用途
CN110372793B (zh) Pd-l1的纳米抗体及其临床应用
CN113583122A (zh) 抗人sema4d抗体及其制备方法和应用
CN114057880B (zh) 一种dll3单克隆抗体
CN104892760B (zh) 抗TNFα的全人源单克隆抗体及其应用
CN112250765A (zh) 一种针对her2的纳米抗体及其应用
CN114409792B (zh) 抗EphB4纳米抗体
CN112239504A (zh) 一种针对pd-l1的纳米抗体及其应用
CN112210009A (zh) 一种针对pd1的单域抗体及其应用
CN116023492A (zh) 一种阻断pd1与pdl1结合的抗人pdl1纳米抗体的制备方法及其编码序列
CN118085092A (zh) 分离的抗人Claudin18.2抗体及其应用
CN116284386A (zh) 一种新型pd1单域抗体的开发

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant